BOLETIN INFORMATIVO Nº 3 – Mayo 2022
Estimados colegas del Programa Nacional de Control de Calidad en Bacteriología (PCC-NAC):
En el presente BOLETIN INFORMATIVO Nº3 enviamos:
- Novedades CLSI 2022: resumen de las novedades más relevantes publicadas en el documento M100S 32nd Edition del Clinical Laboratory Standards Institute (CLSI): “Performance Standards for Antimicrobial Susceptibility Testing; Thirty second Informational Supplement”. M. Rapoport
- Polymyxin susceptibility testing and interpretive breakpoints: recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Pogue JM y col. 2020. Antimicrob Agents Chemother 64:e01495-19. https://doi.org/10.1128/AAC.01495-19.
- Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) position statements on polymyxin B and colistin clinical breakpoints. Satlin M y col. 2020. Clinical Infectious Diseases 71(9). DOI:10.1093/cid/ciaa121
- Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. Humphries R y col. 2021. J Clin Microbiol 59:e00213-21. https://doi.org/10.1128/JCM.00213-21.
Cariños para todos!
Alejandra y Paola
Servicio Antimicrobianos
LNR/LRR en Resistencia a los Antimicrobianos
INEI-ANLIS. “Dr. Carlos G Malbrán”
